Company news

Eupraxia Pharmaceuticals, Inc. news in 2025

Eupraxia Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors

December 16, 2025

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

November 13, 2025

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

November 4, 2025

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

September 29, 2025

Peterson Capital Hosts Canada Growth Conference in Ireland

September 25, 2025

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

September 24, 2025

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

September 22, 2025

Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

September 22, 2025

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

September 2, 2025

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 12, 2025

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

July 22, 2025

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

July 8, 2025

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

June 2, 2025

"Bear-Pit Session" Highlights Peterson Capital's Canada Growth Conference in Montreal

May 15, 2025

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

May 7, 2025

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

May 6, 2025

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

May 5, 2025

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

April 24, 2025

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

March 20, 2025

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

February 25, 2025

Eupraxia Pharmaceuticals Announces CFO Succession

February 18, 2025

Decks in 2025